This is a "connection" page, showing publications co-authored by David Cole and Dennis Watson.
Bystander effect contributes to the antitumor efficacy of CaSm antisense gene therapy in a preclinical model of advanced pancreatic cancer. Mol Ther. 2006 Feb; 13(2):357-65.
CaSm-mediated cellular transformation is associated with altered gene expression and messenger RNA stability. Cancer Res. 2005 Jul 15; 65(14):6228-36.
Establishing a murine pancreatic cancer CaSm model: up-regulation of CaSm is required for the transformed phenotype of murine pancreatic adenocarcinoma. Mol Ther. 2005 Mar; 11(3):363-72.
CaSm antisense gene therapy: a novel approach for the treatment of pancreatic cancer. Anticancer Res. 2003 May-Jun; 23(3A):2007-13.
The cancer-associated Sm-like oncogene: a novel target for the gene therapy of pancreatic cancer. Surgery. 2000 Aug; 128(2):353-60.
Novel immunocompetent murine models representing advanced local and metastatic pancreatic cancer. J Surg Res. 2012 Aug; 176(2):359-66.
CaSm (LSm-1) overexpression in lung cancer and mesothelioma is required for transformed phenotypes. Am J Respir Cell Mol Biol. 2008 Jun; 38(6):671-8.